Latest news with #MNPLLP
Yahoo
7 hours ago
- Business
- Yahoo
MediPharm Announces Voting Results from the 2025 Annual and Special Meeting of Shareholders
TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ('MediPharm' or the 'Company'), a pharmaceutical company specialized in precision-based cannabinoids, today announced the results of matters voted on at its annual and special meeting (the 'Meeting') of holders of common shares ("Shareholders") held today. There were 146 Shareholders represented virtually or by proxy at the Meeting holding an aggregate of 210,726,733 common shares, representing 50.76% of MediPharm's total issued and outstanding common shares as at the record date for the Meeting. As the Meeting was held virtually, all resolutions were passed by way of ballot. Shareholders approved the resolution to fix the number of directors at seven, approved the resolution appointing MNP LLP as auditors, elected all seven management director nominees and approved the resolution relating to unallocated awards under the Company's equity incentive plan. Complete voting results for each of the matters presented at the Meeting are provided below. Board Changes The Company welcomes new directors Emily Jameson and John Medland to the Board. Michael Bumby did not stand for re-election as a director at the Meeting. The Board thanks Mr. Bumby for his invaluable contributions. He was instrumental in the transformative VIVO acquisition which has helped set MediPharm up for its next phase of growth. Complete Voting Results from the Meeting 1. Setting the Number of Directors at Seven The special resolution to fix the number of directors of the Company at seven (7) was approved by Shareholders. Voting results are as set out below: Votes For Votes Against # % # % 159,023,437 75.46 51,703,294 24.54 2. Election of Directors Each of the Company's nominees were elected as directors of MediPharm for the ensuing year or until their successors are elected or appointed. Voting results for each director nominee are as set out below: Nominee # Management Nominees Chris Halyk 144,007,422 Emily Jameson 144,289,930 John Medland 144,182,233 David Pidduck 142,961,350 Shelley Potts 144,156,682 Keith Strachan 140,531,927 Chris Taves 143,500,811 Dissident Nominees John Fowler 51,801,045 Alan D. Lewis 51,681,657 David Lontini 51,611,107 Demetrios Mallios 51,531,594 Regan McGee 51,634,357 Scott Walters 51,677,144 3. Appointment of Auditor MNP LLP, Chartered Professional Accountants, was appointed as auditor of MediPharm until the next annual meeting of the holders of the Shareholders at remuneration to be fixed by the directors. Voting results are as set out below: Votes For Votes Withheld # % # % 191,303,393 90.78 19,423,340 9.22 4. Approval of Unallocated Awards Under Equity Incentive Plan A resolution to approve, among other things, the unallocated awards available under the Company's equity incentive plan was approved by Shareholders. Voting results are as set out below: Votes For Votes Against # % # % 101,750,700 50.14% 101,162,710 49.86 About MediPharm Labs Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company's current foreign drug manufacturing site registration with the US FDA. In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Germany through Beacon Medical Australia PTY Ltd. and Beacon Medical Germany GMBH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with Physician consultations for medical cannabis education and prescriptions. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates. Investor Contact: MediPharm Labs Investor RelationsTelephone: +1 416.913.7425Email: investors@ Media Contact: John VincicOakstrom Advisors+1 (647) 402-6375john@ Cautionary Note Regarding Forward-Looking Information: This news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking statements') within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as 'expects', or 'does not expect', 'is expected', 'anticipates' or 'does not anticipate', 'plans', 'budget', 'scheduled', 'forecasts', 'estimates', 'believes' or 'intends' or variations of such words and phrases or stating that certain actions, events or results 'may' or 'could', 'would', 'might' or 'will' be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm's continuous disclosure filings, available on the SEDAR+ website at There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Business
- Yahoo
MediPharm Announces Voting Results from the 2025 Annual and Special Meeting of Shareholders
TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ('MediPharm' or the 'Company'), a pharmaceutical company specialized in precision-based cannabinoids, today announced the results of matters voted on at its annual and special meeting (the 'Meeting') of holders of common shares ("Shareholders") held today. There were 146 Shareholders represented virtually or by proxy at the Meeting holding an aggregate of 210,726,733 common shares, representing 50.76% of MediPharm's total issued and outstanding common shares as at the record date for the Meeting. As the Meeting was held virtually, all resolutions were passed by way of ballot. Shareholders approved the resolution to fix the number of directors at seven, approved the resolution appointing MNP LLP as auditors, elected all seven management director nominees and approved the resolution relating to unallocated awards under the Company's equity incentive plan. Complete voting results for each of the matters presented at the Meeting are provided below. Board Changes The Company welcomes new directors Emily Jameson and John Medland to the Board. Michael Bumby did not stand for re-election as a director at the Meeting. The Board thanks Mr. Bumby for his invaluable contributions. He was instrumental in the transformative VIVO acquisition which has helped set MediPharm up for its next phase of growth. Complete Voting Results from the Meeting 1. Setting the Number of Directors at Seven The special resolution to fix the number of directors of the Company at seven (7) was approved by Shareholders. Voting results are as set out below: Votes For Votes Against # % # % 159,023,437 75.46 51,703,294 24.54 2. Election of Directors Each of the Company's nominees were elected as directors of MediPharm for the ensuing year or until their successors are elected or appointed. Voting results for each director nominee are as set out below: Nominee # Management Nominees Chris Halyk 144,007,422 Emily Jameson 144,289,930 John Medland 144,182,233 David Pidduck 142,961,350 Shelley Potts 144,156,682 Keith Strachan 140,531,927 Chris Taves 143,500,811 Dissident Nominees John Fowler 51,801,045 Alan D. Lewis 51,681,657 David Lontini 51,611,107 Demetrios Mallios 51,531,594 Regan McGee 51,634,357 Scott Walters 51,677,144 3. Appointment of Auditor MNP LLP, Chartered Professional Accountants, was appointed as auditor of MediPharm until the next annual meeting of the holders of the Shareholders at remuneration to be fixed by the directors. Voting results are as set out below: Votes For Votes Withheld # % # % 191,303,393 90.78 19,423,340 9.22 4. Approval of Unallocated Awards Under Equity Incentive Plan A resolution to approve, among other things, the unallocated awards available under the Company's equity incentive plan was approved by Shareholders. Voting results are as set out below: Votes For Votes Against # % # % 101,750,700 50.14% 101,162,710 49.86 About MediPharm Labs Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company's current foreign drug manufacturing site registration with the US FDA. In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Germany through Beacon Medical Australia PTY Ltd. and Beacon Medical Germany GMBH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with Physician consultations for medical cannabis education and prescriptions. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates. Investor Contact: MediPharm Labs Investor RelationsTelephone: +1 416.913.7425Email: investors@ Media Contact: John VincicOakstrom Advisors+1 (647) 402-6375john@ Cautionary Note Regarding Forward-Looking Information: This news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking statements') within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as 'expects', or 'does not expect', 'is expected', 'anticipates' or 'does not anticipate', 'plans', 'budget', 'scheduled', 'forecasts', 'estimates', 'believes' or 'intends' or variations of such words and phrases or stating that certain actions, events or results 'may' or 'could', 'would', 'might' or 'will' be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm's continuous disclosure filings, available on the SEDAR+ website at There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
Yahoo
04-06-2025
- Business
- Yahoo
KITS Announces Voting Results from 2025 Annual General Meeting of Shareholders
VANCOUVER, BC, June 4, 2025 /CNW/ - Kits Eyecare Ltd. (TSX: KITS) ("KITS" or the "Company") is pleased to announce the results of the matters voted upon at its annual general meeting of shareholders held on June 4, 2025 (the "Meeting"), which included the election of directors. All of the resolutions were conducted by electronic ballot and the voting results are set out below. 1. Election of Directors The following six nominees were elected by the shareholders as directors of the Company for the ensuing year and each of the directors received the following votes: Election of Directors Votes For % For Votes Withheld % Withheld Roger Hardy 24,193,454 99.92 % 19,880 0.08 % Arshil Abdulla 24,211,034 99.99 % 2,300 0.01 % Nick Bozikis 24,192,149 99.91 % 21,185 0.09 % Peter Lee 22,987,137 94.94 % 1,226,197 5.06 % Anne Kavanagh 24,213,297 100.00 % 37 0.00 % Andrew Reid 24,192,149 99.91 % 21,185 0.09 % 2. Re-appointment of MNP LLP as the Company's Auditors MNP LLP was re-appointed as the Company's auditors to hold office until the next annual meeting of shareholders of the Company (and the directors were authorized to fix their remuneration) as follows:Number of Votes Percentage of Votes For 24,348,232 100.00 % Withheld 37 0.00 % Total 24,348,269 100.00 % About KITS KITS makes eyecare easy. KITS is a leading vertically integrated digital eyecare brand providing eyewear for eyes everywhere. We offer customers access to a vast selection of contact lenses and eyeglasses, including our own exclusive KITS designed products, as well as a robust suite of online vision tools. Our efficient digital platform, backed by our industry-leading manufacturing and designs, removes intermediaries, and enables us to offer great prices and deliver made to order personalized products with incredible care and accuracy. We are creating disruption in the industry by constantly pursuing cutting-edge technologies to enable the best customer experience, including online eyewear fitting tools, and virtual try-on for glasses. We strive to delight our customers with our competitive prices, a convenient digital shopping experience, fast and reliable delivery options, and an unrelenting focus on earning our customers' lifelong trust. For more information on KITS, visit: SOURCE KITS Eyecare Ltd. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
04-06-2025
- Business
- Cision Canada
KITS Announces Voting Results from 2025 Annual General Meeting of Shareholders
VANCOUVER, BC, June 4, 2025 /CNW/ - Kits Eyecare Ltd. (TSX: KITS) ("KITS" or the "Company") is pleased to announce the results of the matters voted upon at its annual general meeting of shareholders held on June 4, 2025 (the "Meeting"), which included the election of directors. All of the resolutions were conducted by electronic ballot and the voting results are set out below. 1. Election of Directors The following six nominees were elected by the shareholders as directors of the Company for the ensuing year and each of the directors received the following votes: 2. Re-appointment of MNP LLP as the Company's Auditors MNP LLP was re-appointed as the Company's auditors to hold office until the next annual meeting of shareholders of the Company (and the directors were authorized to fix their remuneration) as follows: About KITS KITS makes eyecare easy. KITS is a leading vertically integrated digital eyecare brand providing eyewear for eyes everywhere. We offer customers access to a vast selection of contact lenses and eyeglasses, including our own exclusive KITS designed products, as well as a robust suite of online vision tools. Our efficient digital platform, backed by our industry-leading manufacturing and designs, removes intermediaries, and enables us to offer great prices and deliver made to order personalized products with incredible care and accuracy. We are creating disruption in the industry by constantly pursuing cutting-edge technologies to enable the best customer experience, including online eyewear fitting tools, and virtual try-on for glasses. We strive to delight our customers with our competitive prices, a convenient digital shopping experience, fast and reliable delivery options, and an unrelenting focus on earning our customers' lifelong trust. For more information on KITS, visit:
Cision Canada
01-05-2025
- Business
- Cision Canada
Frontenac Mortgage Investment Corporation Announces Expected Delay in Filing Annual Financial Statements
SHARBOT LAKE, ON, May 1, 2025 /CNW/ - Frontenac Mortgage Investment Corporation (" FMIC" or the " Company") announced today that it anticipates a delay in filing its annual financial statements for the year ended December 31, 2024, the related management's discussion and analysis and the management certifications of annual filings (collectively, the " Required Documents") before the April 30, 2025 deadline (the " Filing Deadline"). The Company has been advised by its external auditors, MNP LLP, that while the Company is working diligently with MNP LLP in the process of performing the audit for the year ended December 31, 2024, MNP LLP is experiencing delays in the completion of the audit which will result in the Company being delayed in filing the Required Documents by the Filing Deadline. The Company has applied to the Ontario Securities Commission (the " OSC"), as principal Canadian regulator for the Company, for the imposition of a management cease trade order (" MCTO") under National Policy 12-203 – Management Cease Trade Orders (" NP 12-203") throughout the duration of the default. The MCTO, if approved, would generally not affect the ability of persons who are not management of the Company to trade in its securities. There is no certainty that the MCTO will be issued. In the event that the MCTO is not issued, the OSC may issue a general cease trade order against the Company for failure to file the Required Documents within the prescribed time period. The Company confirms that it will satisfy the provisions of the alternative information guidelines under NP 12-203 by issuing bi-weekly default status reports in the form of news releases for so long as it remains in default of the above-noted filing requirements and further confirms there is no other material information relating to its affairs that has not been generally disclosed. FMIC's management is working diligently to remedy the situation and anticipates the Required Documents will be filed as soon as they are available, currently expected by June 30, 2025. FMIC intends to provide updates on further developments in respect of this matter promptly following their occurrence. Other than as disclosed herein, the Company is up to date in its filing obligations. Forward-Looking Statements This press release contains certain forward-looking statements and forward-looking information (collectively referred to herein as " forward-looking statements") within the meaning of applicable Canadian securities laws, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company, and specifically includes statements relating to the timing of the filing of the Required Documents, the redemption of shares in accordance with its Pro Rata Redemption Plan and the issuance of an MCTO. All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "anticipate", "achieve", "could", "believe", "plan", "intend", "objective", "continuous", "ongoing", "estimate", "outlook", "expect", "may", "will", "project", "should" or similar words, including negatives thereof, suggesting future outcomes. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors beyond FMIC's ability to predict or control which may cause actual events, results, performance, or achievements of FMIC to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein. Forward-looking statements are not a guarantee of future performance. Although FMIC believes that any forward-looking statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such statements, there can be no assurance that any such forward-looking statements will prove to be accurate. Actual results may vary, and vary materially, from those expressed or implied by the forward-looking statements herein. Accordingly, readers are advised to rely on their own evaluation of the risks and uncertainties inherent in forward-looking statements herein and should not place undue reliance upon such forward-looking statements. All forward-looking statements herein are qualified by this cautionary statement. Any forward-looking statements herein are made only as of the date hereof, and except as required by applicable laws, FMIC assumes no obligation and disclaims any intention to update or revise any forward-looking statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward-looking statements herein, whether as a result of new information, future events or results, or otherwise.
